VAXCYTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
VAXCYTE, INC. (PCVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $32.09 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-24
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $20.75, a 52.17% decline year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $46.04, a 2.62% decline year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-09-30 was $52.05, a 69.82% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-06-30 was $43.38, a 39.98% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $32.09, a 34.99% decline from fiscal 2024.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $49.36, a 71.75% increase from fiscal 2023.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $28.74, a 52.22% increase from fiscal 2022.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $18.88, a 28.87% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $32.09 10-K · filed 2026-02-24 | ||||
| 2025-06-30 | $20.75 10-Q · filed 2025-08-06 | $37660000.00 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | $46.04 10-Q · filed 2025-05-07 | ||||
| 2024-12-31 | $49.36 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $52.05 10-Q · filed 2024-11-05 | $46.46 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | $43.38 10-Q · filed 2025-08-06 | $45.86 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $47.28 10-Q · filed 2025-05-07 | ||||
| 2023-12-31 | $28.74 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $30.65 10-Q · filed 2024-11-05 | $28.04 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | $30.99 10-Q · filed 2024-08-06 | $27.28 10-Q · filed 2024-08-06 | $27.78 10-Q · filed 2023-08-08 | ||
| 2023-03-31 | $27.18 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | $18.88 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $18.01 10-Q · filed 2023-11-06 | $16.39 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | $14.60 10-Q · filed 2023-08-08 | $15.88 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | $16.34 10-Q · filed 2023-05-08 | ||||
| 2021-12-31 | $14.65 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $17.00 10-Q · filed 2022-11-07 | $14.37 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | $13.91 10-Q · filed 2022-08-08 | $14.14 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $17.70 10-Q · filed 2022-05-09 | ||||
| 2020-12-31 | $9.62 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | $29.83 10-Q · filed 2021-11-10 | $8.17 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $8.41 10-Q · filed 2021-08-11 | $8.08 10-Q · filed 2021-08-11 | |||
| 2020-03-31 | $2.58 10-Q · filed 2021-05-11 | ||||
| 2019-12-31 | $1.52 10-K · filed 2021-03-29 | ||||
| 2019-09-30 | $2.31 10-Q · filed 2020-11-12 | $1.51 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $0.88 10-Q · filed 2020-08-12 | $0.87 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $1.38 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |